Related Experiment Videos

[Response to the treatment with indomethacin in persistent ductus arteriosus]

G Flores-Nava1, H Joachín-Roy, M L González-Aguado

  • 1Unidad de Cuidados Intensivos Neonatales, Hospital de Gineco-Obstetricia Luis Castelazo Ayala, Instituto Mexicano del Seguro Social, D.F.

Insights

Indomethacin effectively closes the persistent arterial duct in newborns, improving survival rates. This study highlights its benefits for critically ill infants in the Intensive Care Unit.

Area of Science:

  • Neonatal Cardiology
  • Pediatric Critical Care Medicine
  • Pharmacology

Context:

  • Persistent arterial duct (PDA) is a common condition in newborns requiring intensive care.
  • Diagnosis of PDA often occurs after the fifth day of life, with characteristic clinical findings.
  • Radiological and echocardiographic assessments are crucial for diagnosing PDA and its severity.

Purpose:

  • To review clinical findings, diagnostic methods, and treatment outcomes for persistent arterial duct in neonates.
  • To evaluate the efficacy of indomethacin in closing the arterial duct.
  • To compare outcomes between neonates treated with indomethacin and those who were not.

Summary:

  • A review of 46 neonates with PDA revealed common clinical signs like murmurs and hyperdynamic precordium.
  • Echocardiography showed an average left atrium/aorta ratio of 1.4.
  • Indomethacin successfully closed the duct in 84% of treated infants, with improved survival compared to untreated infants.

Impact:

  • Indomethacin demonstrates significant efficacy in closing the persistent arterial duct in neonates.
  • Treatment with indomethacin is associated with improved survival rates in critically ill newborns with PDA.
  • These findings support the use of indomethacin as a primary treatment for selected cases of persistent arterial duct.

Related Concept Videos